2023 ASCO| Cinda Biology announces the latest clinical data of LAG-3 monoclonal antibody immunotherapy

On June 5, 2023, Cinda Bio announced the clinical phase Ib data of IBI110 (anti-LAG-3 monoclonal antibody) in the treatment of first-line gastric cancer and first-line liver cancer at the 2023 annual meeting of American Society of Clinical Oncology (ASCO) (study registration number: NCT04085185).

Efficacy and safety of IBI110 (anti-LAG-3 mab) plus sintilimab in first-line advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: update from a phase Ib study

This phase 1b study was designed to evaluate the safety, tolerability, and efficacy of IBI110 combined with sindilumab and chemotherapy in subjects with first-line gastric or gastroesophageal junction adenocarcinoma. Among the findings:

Seventeen subjects with HER2-negative, previously untreated, inoperable gastric or gastroesophageal junction adenocarcinoma received 200mg of IBI110 plus sintilimab and chemotherapy (XELOX). As of March 22, 2023, the median follow-up was 15.8 months (95% CI, 13.4 to 16.6). Among them, 15 patients achieved partial remission, and the ORR was 88.2%. The median DoR was 10.6 months (95% CI, 2.5-14.4); The median progression-free survival (PFS) was 12.9 months (95% CI, 3.8-15.8). The median OS was not mature.

In terms of safety, 11 patients experienced treatment-related adverse events (TRAEs) of grade 3 or higher, the most common of which were thrombocytopenia (23.5%) and neutropenia (17.6%). Three patients experienced grade 3 or above immune-related adverse events (irAE). No treatment-related deaths occurred.

Efficacy and safety of IBI110 (anti-LAG-3 mab) plus sintilimab in advanced first-line hepatocellular carcinoma: results of a phase Ib study

"This phase Ib expansion cohort study was designed to evaluate the safety, tolerability, and efficacy of IBI110 in combination with sintilimab and lenvatinib in subjects with first-line hepatocellular carcinoma." Among the findings:

Twenty-eight subjects with unresectable or metastatic hepatocellular carcinoma who had not received previous systemic therapy were treated with IBI110 (200mg, Q3W) in combination with sintilimab and lenvatinib, 27 of whom completed at least one post-baseline tumor assessment. Until March 22, 2023, the median follow-up was 12.2 months (95% CI, 11.0-12.6). The objective response rate (ORR) and disease control rate (DCR) were 29.6% and 85.2%, respectively. The median progression-free survival (PFS) was 9.9 months (95% CI, 5.7-NC). PFS data are not mature, and further follow-up is needed. The median OS has not been reached.

In terms of safety, 16 patients experienced treatment-related adverse events (TRAEs) of grade 3 or higher. The most common TRAEs of grade 3 or higher were hypertension (25%) and thrombocytopenia (7.1%).